Aurinia Pharmaceuticals Inc AUPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
-
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
-
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
-
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
-
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
-
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Trading Information
- Previous Close Price
- $7.16
- Day Range
- $7.11–7.31
- 52-Week Range
- $4.71–10.05
- Bid/Ask
- $7.16 / $7.29
- Market Cap
- $1.04 Bil
- Volume/Avg
- 790,979 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.05
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 300
- Website
- https://www.auriniapharma.com
Comparables
Valuation
|
Metric
|
AUPH
|
TERN
|
XENE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.85 | 2.75 | 3.46 |
Price/Sales | 5.05 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AUPH
TERN
XENE
Financial Strength
|
Metric
|
AUPH
|
TERN
|
XENE
|
|---|---|---|---|
Quick Ratio | 4.63 | 20.57 | 23.09 |
Current Ratio | 5.33 | 21.02 | 23.27 |
Interest Coverage | −11.69 | — | — |
Quick Ratio
AUPH
TERN
XENE
Profitability
|
Metric
|
AUPH
|
TERN
|
XENE
|
|---|---|---|---|
Return on Assets (Normalized) | −2.14% | −28.87% | −19.13% |
Return on Equity (Normalized) | −3.06% | −30.36% | −20.01% |
Return on Invested Capital (Normalized) | −4.73% | −34.37% | −24.47% |
Return on Assets
AUPH
TERN
XENE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lkbmdsjm | Qlxv | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ykssfnrd | Hysgsm | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Djtcpmkp | Tnlmyl | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zlgbdlb | Wqhhwcl | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kxbkhhxp | Jrnpr | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xqkgcbfc | Fmby | $28.1 Bil | |||
| Moderna Inc
MRNA
| Zylmbpj | Cxjst | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ddwgmplz | Xsxq | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hzwywgcnb | Bvvfv | $13.4 Bil | |||
| Incyte Corp
INCY
| Hwtyycr | Rsjccp | $12.7 Bil |
United States